ANRO

Alto Neuroscience, Inc.

Price Chart

Latest Quote

$18.26

-1.77 (-8.84%)

Current Price

Previous Close	$20.03
Open	$19.80
Day High	$20.21
Day Low	$17.95
Volume	395,105

Fetched: 2026-06-06T13:18:08

Stock Information

Shares Outstanding	35.09M
Total Debt	$21.91M
Cash Equivalents	$263.76M
Net Income	$-74.31M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$640.82M
EPS (TTM)	$-2.43
Exchange	NYQ

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$398.96M
Income	$-74.31M
Book/sh	$6.94
Cash/sh	$7.52
Employees	68

Financial Ratios

Quick Ratio	20.11
Current Ratio	20.52
Debt/Eq	9.00

Returns & Margins

ROA	-21.71%
ROE	-38.86%

Ownership

Insider Ownership	4.55%
Institutional Ownership	82.05%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-5.32
P/B	2.63

Analyst Data

Recommendation	strong_buy
Target Price	$35.13

Technical Indicators

SMA20	$21.30
SMA50	$22.99
SMA200	$15.57
RSI	25.26
ATR	1.3776

Shares Float	23.95M
Short Float	5.49%
Short Ratio	5.29
Rel Volume	1.25

Performance History

Week	-9.02%
Month	-25.44%
Quarter	-12.04%
6 Months	+36.37%
YTD	+10.07%
Year	+645.31%
10 Years	-11.79%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-05	$18.26	414,100
2026-06-04	$20.03	366,800
2026-06-03	$18.85	471,500
2026-06-02	$18.71	321,100
2026-06-01	$19.80	219,400
2026-05-29	$20.07	171,000
2026-05-28	$20.22	247,200
2026-05-27	$20.44	153,200
2026-05-26	$21.06	413,600
2026-05-22	$21.22	271,400
2026-05-21	$21.54	263,900
2026-05-20	$20.78	211,700
2026-05-19	$20.45	330,300
2026-05-18	$21.80	689,900
2026-05-15	$22.98	376,300
2026-05-14	$23.59	509,800
2026-05-13	$22.85	416,700
2026-05-12	$24.63	206,900
2026-05-11	$24.53	389,400
2026-05-08	$24.26	171,200
2026-05-07	$24.07	614,800
2026-05-06	$24.49	352,800

About Alto Neuroscience, Inc.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

📰 Latest News

Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing

Motley Fool • 2026-05-27T05:19:24Z

Top 1% Alto Neuroscience Plummets On Its Shocking Schizophrenia Miss

Investor's Business Daily • 2026-04-02T20:10:00Z

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires • 2026-04-02T19:57:32Z

Update: Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data

MT Newswires • 2026-04-02T18:36:31Z

Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM

BioPharma Dive • 2026-04-02T12:20:00Z

Alto Neuroscience CFO Nick Smith on Firm’s $120 Million Private Placement

NYSE • 2026-03-23T15:14:09Z

Alto Neuroscience, Inc.'s (NYSE:ANRO) Intrinsic Value Is Potentially 58% Above Its Share Price

Simply Wall St. • 2026-02-05T11:20:31Z

Alto Neuroscience, Inc. (NYSE:ANRO) is definitely on the radar of institutional investors who own 33% of the company

Simply Wall St. • 2025-12-26T13:36:20Z

Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year?

Zacks • 2025-11-14T14:40:03Z

Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?

Zacks • 2025-11-10T16:21:00Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$2,469,000	$1,375,000	$1,370,000	$0
Total Expenses	$66,364,000	$68,610,000	$37,809,000	$27,455,000
Other Income Expense	$-1,008,000	$-297,000	$525,000	$-369,000
Other Non Operating Income Expenses	$-327,000	$-297,000	$525,000	-
Net Non Operating Interest Income Expense	$4,134,000	$7,476,000	$979,000	$114,000
Interest Expense Non Operating	$2,469,000	$1,375,000	$1,370,000	$0
Operating Expense	$66,364,000	$68,610,000	$37,809,000	$27,455,000
General And Administrative Expense	$20,745,000	$21,614,000	$7,518,000	$5,504,000
Other Operating Expenses	-	-	-	$-1,737,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-63,238,000	$-61,431,000	$-36,305,000	$-27,710,000
Net Interest Income	$4,134,000	$7,476,000	$979,000	$114,000
Interest Income	$6,603,000	$8,851,000	$2,349,000	$114,000
Normalized Income	$-62,557,000	$-61,431,000	$-36,305,000	$-27,341,000
Net Income From Continuing And Discontinued Operation	$-63,238,000	$-61,431,000	$-36,305,000	$-27,710,000
Total Operating Income As Reported	$66,364,000	$68,610,000	$-37,809,000	$-29,192,000
Net Income Common Stockholders	$-63,238,000	$-61,431,000	$-36,305,000	$-27,710,000
Net Income	$-63,238,000	$-61,431,000	$-36,305,000	$-27,710,000
Net Income Including Noncontrolling Interests	$-63,238,000	$-61,431,000	$-36,305,000	$-27,710,000
Net Income Continuous Operations	$-63,238,000	$-61,431,000	$-36,305,000	$-27,710,000
Pretax Income	$-63,238,000	$-61,431,000	$-36,305,000	$-27,710,000
Special Income Charges	$-681,000	$0	-	-
Interest Income Non Operating	$6,603,000	$8,851,000	$2,349,000	$114,000
Operating Income	$-66,364,000	$-68,610,000	$-37,809,000	$-27,455,000
Per Share
Diluted EPS	$-2.19	$-2.50	$-1.42	$-2.13
Basic EPS	$-2.19	$-2.50	$-1.42	$-2.13
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-59,427,000	$-59,554,000	$-34,562,000	$-26,999,000
Total Unusual Items	$-681,000	$0	$525,000	$-369,000
Total Unusual Items Excluding Goodwill	$-681,000	$0	$525,000	$-369,000
Reconciled Depreciation	$661,000	$502,000	$373,000	$342,000
EBITDA (Bullshit earnings)	$-60,108,000	$-59,554,000	$-34,562,000	$-27,368,000
EBIT	$-60,769,000	$-60,056,000	$-34,935,000	$-27,710,000
Diluted Average Shares	$28,852,000	$24,602,000	$25,574,360	$12,980,000
Basic Average Shares	$28,852,000	$24,602,000	$25,574,360	$12,980,000
Diluted NI Availto Com Stockholders	$-63,238,000	$-61,431,000	$-36,305,000	$-27,710,000
Other Special Charges	$681,000	-	-	-
Research And Development	$45,619,000	$46,996,000	$30,291,000	$23,688,000
Selling General And Administration	$20,745,000	$21,614,000	$7,518,000	$5,504,000
Other Gand A	$20,745,000	$21,614,000	$7,518,000	$5,504,000
Gain On Sale Of Security	-	-	$525,000	$-369,000

Fetched: 2026-06-06

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$151,142,000	$151,460,000	$-71,672,000	$-38,406,000
Total Assets	$184,689,000	$177,542,000	$86,628,000	$50,854,000
Total Non Current Assets	$6,971,000	$8,205,000	$1,237,000	$1,634,000
Other Non Current Assets	$838,000	$504,000	$131,000	$461,000
Current Assets	$177,718,000	$169,337,000	$85,391,000	$49,220,000
Prepaid Assets	$1,234,000	$1,108,000	$522,000	$330,000
Cash Cash Equivalents And Short Term Investments	$176,484,000	$168,229,000	$82,548,000	$48,344,000
Cash And Cash Equivalents	$176,484,000	$168,229,000	$82,548,000	$48,344,000
Other Current Assets	-	$30,000	$112,000	$213,000
Current Deferred Assets	-	$0	$2,209,000	$0
Receivables	-	-	$8,000	$333,000
Other Receivables	-	-	$8,000	$333,000
Accounts Receivable	-	-	-	$333,000
Debt
Total Debt	$23,958,000	$16,944,000	$9,986,000	$9,748,000
Long Term Debt And Capital Lease Obligation	$22,222,000	$16,074,000	$9,861,000	$9,465,000
Long Term Debt	$18,399,000	$11,558,000	$9,861,000	$9,465,000
Current Debt And Capital Lease Obligation	$1,736,000	$870,000	$125,000	$283,000
Current Debt	$585,000	-	-	-
Other Current Borrowings	$585,000	-	-	-
Liabilities
Total Liabilities Net Minority Interest	$33,547,000	$26,082,000	$158,300,000	$89,260,000
Total Non Current Liabilities Net Minority Interest	$22,222,000	$16,074,000	$152,690,000	$83,700,000
Current Liabilities	$11,325,000	$10,008,000	$5,610,000	$5,560,000
Payables And Accrued Expenses	$9,589,000	$9,138,000	$5,485,000	$5,277,000
Interest Payable	$118,000	$78,000	$84,000	$0
Payables	$1,878,000	$1,579,000	$1,074,000	$1,606,000
Accounts Payable	$1,878,000	$1,579,000	$1,074,000	$1,606,000
Derivative Product Liabilities	-	$0	$1,352,000	$1,877,000
Other Current Liabilities	-	-	$515,000	-
Other Non Current Liabilities	-	-	-	$123,000
Equity
Common Stock Equity	$151,142,000	$151,460,000	$-71,672,000	$-38,406,000
Total Equity Gross Minority Interest	$151,142,000	$151,460,000	$-71,672,000	$-38,406,000
Stockholders Equity	$151,142,000	$151,460,000	$-71,672,000	$-38,406,000
Gains Losses Not Affecting Retained Earnings	$22,000	$-101,000	$-79,000	$-46,000
Other Equity Adjustments	$22,000	$-101,000	$-79,000	$-46,000
Retained Earnings	$-201,634,000	$-138,396,000	$-76,965,000	$-40,660,000
Preferred Securities Outside Stock Equity	-	$0	$141,477,000	$72,235,000
Other
Ordinary Shares Number	$31,923,521	$26,986,560	$25,574,360	$25,574,360
Share Issued	$31,923,521	$26,986,560	$25,574,360	$25,574,360
Tangible Book Value	$151,142,000	$151,460,000	$-71,672,000	$-38,406,000
Invested Capital	$170,126,000	$163,018,000	$-61,811,000	$-28,941,000
Working Capital	$166,393,000	$159,329,000	$79,781,000	$43,660,000
Capital Lease Obligations	$4,974,000	$5,386,000	$125,000	$283,000
Total Capitalization	$169,541,000	$163,018,000	$-61,811,000	$-28,941,000
Additional Paid In Capital	$352,751,000	$289,954,000	$5,372,000	$2,300,000
Capital Stock	$3,000	$3,000	$0	$0
Common Stock	$3,000	$3,000	$0	$0
Long Term Capital Lease Obligation	$3,823,000	$4,516,000	$0	-
Current Capital Lease Obligation	$1,151,000	$870,000	$125,000	$283,000
Current Accrued Expenses	$7,711,000	$7,559,000	$4,411,000	$3,671,000
Net PPE	$6,133,000	$7,701,000	$1,106,000	$1,173,000
Accumulated Depreciation	$-1,526,000	$-1,004,000	$-684,000	$-579,000
Gross PPE	$7,659,000	$8,705,000	$1,790,000	$1,752,000
Leases	$246,000	$246,000	$0	-
Other Properties	$6,386,000	$7,341,000	$1,201,000	$1,132,000
Machinery Furniture Equipment	$1,027,000	$1,118,000	$589,000	$620,000
Properties	$0	$0	$0	-
Buildings And Improvements	-	$5,035,000	$0	-

Fetched: 2026-06-06

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-51,793,000	$-49,499,000	$-33,918,000	$-21,126,000
Operating Activities
Operating Cash Flow	$-51,769,000	$-47,424,000	$-33,448,000	$-20,394,000
Cash Flow From Continuing Operating Activities	$-51,769,000	$-47,424,000	$-33,448,000	$-20,394,000
Operating Gains Losses	$837,000	$52,000	$140,000	$369,000
Investing Activities
Capital Expenditure	$-24,000	$-2,075,000	$-470,000	$-732,000
Investing Cash Flow	$-24,000	$-2,075,000	$-470,000	$-732,000
Cash Flow From Continuing Investing Activities	$-24,000	$-2,075,000	$-470,000	$-732,000
Capital Expenditure Reported	$-24,000	$-2,075,000	$-470,000	$-732,000
Financing Activities
Repurchase Of Capital Stock	$-167,000	$0	-	-
Issuance Of Capital Stock	$50,000,000	$137,579,000	$70,000,000	$34,305,000
Financing Cash Flow	$60,078,000	$135,691,000	$68,130,000	$43,789,000
Cash Flow From Continuing Financing Activities	$60,078,000	$135,691,000	$68,130,000	$43,789,000
Net Other Financing Charges	$67,000	$-2,075,000	$-2,051,000	$-341,000
Net Common Stock Issuance	$49,833,000	$137,579,000	$0	$43,000
Common Stock Issuance	$50,000,000	$137,579,000	$0	$43,000
Net Preferred Stock Issuance	-	$0	$70,000,000	$34,262,000
Preferred Stock Issuance	-	$0	$70,000,000	$34,262,000
Other
Repayment Of Debt	$-10,213,000	$0	-	-
Issuance Of Debt	$19,688,000	$0	$0	$9,825,000
Interest Paid Supplemental Data	$1,660,000	$999,000	$912,000	$0
End Cash Position	$176,984,000	$168,729,000	$82,548,000	$48,344,000
Beginning Cash Position	$168,729,000	$82,548,000	$48,344,000	$25,705,000
Effect Of Exchange Rate Changes	$-30,000	$-11,000	$-8,000	$-24,000
Changes In Cash	$8,285,000	$86,192,000	$34,212,000	$22,663,000
Proceeds From Stock Option Exercised	$703,000	$187,000	$181,000	-
Common Stock Payments	$-167,000	$0	-	-
Net Issuance Payments Of Debt	$9,475,000	$0	$0	$9,825,000
Net Long Term Debt Issuance	$9,475,000	$0	$0	$9,825,000
Long Term Debt Payments	$-10,213,000	$0	-	-
Long Term Debt Issuance	$19,688,000	$0	$0	$9,825,000
Change In Working Capital	$33,000	$4,060,000	$-698,000	$4,579,000
Change In Payables And Accrued Expense	$-68,000	$4,523,000	$-989,000	$3,480,000
Change In Accrued Expense	$-289,000	$4,007,000	$-357,000	$2,474,000
Change In Payable	$221,000	$516,000	$-632,000	$1,006,000
Change In Account Payable	$221,000	$516,000	$-632,000	$1,006,000
Change In Prepaid Assets	$101,000	$-463,000	$291,000	$-59,000
Other Non Cash Items	$1,830,000	$1,762,000	$151,000	$263,000
Stock Based Compensation	$8,108,000	$7,631,000	$2,891,000	$1,763,000
Depreciation Amortization Depletion	$661,000	$502,000	$373,000	$342,000
Depreciation And Amortization	$661,000	$502,000	$373,000	$342,000
Depreciation	$661,000	$502,000	-	-
Net Income From Continuing Operations	$-63,238,000	$-61,431,000	$-36,305,000	$-27,710,000
Change In Receivables	-	-	$325,000	$1,158,000
Changes In Account Receivables	-	-	$325,000	$1,158,000
Gain Loss On Investment Securities	-	-	$-525,000	$369,000

Fetched: 2026-06-06